GlassScriptPhysician profile
Jennifer M Werrell
NPI 1033146964
$6,292.28
in general payments reported to CMS, 2019-2025
23 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $377 · 2021: $2,248 · 2022: $910 · 2023: $616 · 2024: $605 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,466.36 | 2021-2025 | Acuvue |
| Allergan, INC. | $726.01 | 2019-2022 | |
| Abbvie INC. | $630.48 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Alcon Vision LLC | $528.96 | 2020-2025 | Precision7, Rocklatan, Precision 1 |
| Coopervision INC. | $495.29 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $328.85 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $314.27 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $288.96 | 2019-2021 | |
| Glaukos Corporation | $247.71 | 2021-2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $230.66 | 2022-2025 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $160.56 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $142.63 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $135.87 | 2021 | |
| Horizon Therapeutics Plc | $124.98 | 2023 | Tepezza |
| Optos, INC. | $109.23 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $84.84 | 2025 | |
| Aerie Pharmaceuticals, INC. | $65.45 | 2021 | |
| Eyevance Pharmaceuticals LLC | $59.77 | 2021-2022 | |
| Sight Sciences, INC. | $47.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.92 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $24.99 | 2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $24.81 | 2025 | Iluvien |
| Astellas Pharma US INC | $16.41 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Werrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.